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SUMMARY
To address uncertainty of whether clinical stage groupings (cTNM) for esophageal cancer share 
prognostic implications with pathologic groupings after esophagectomy alone (pTNM), we report 
data—simple descriptions of patient characteristics, cancer categories, and non-risk-adjusted 
survival—for clinically staged patients from the Worldwide Esophageal Cancer Collaboration 
(WECC). Thirty-three institutions from six continents submitted data using variables with standard 
definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from 
first management decision. Of 22,123 clinically staged patients, 8,156 had squamous cell 
carcinoma, 13,814 adenocarcinoma, 116 adenosquamous carcinoma, and 37 undifferentiated 
carcinoma. Patients were older (62 years) men (80%) with normal body mass index (18.5–25 
mg/kg2, 47%), little weight loss (2.4 ± 7.8 kg), 0–1 ECOG performance status (67%), and history 
of smoking (67%). Cancers were cT1 (12%), cT2 (22%), cT3 (56%), cNO (44%), cMO (95%), 
and cG2–G3 (89%); most involved the distal esophagus (73%). Non-risk-adjusted survival for 
squamous cell carcinoma was not distinctive for early cT or cN; for adenocarcinoma, it was 
distinctive for early versus advanced cT and for cNO versus cN+. Patients with early cancers had 
worse survival and those with advanced cancers better survival than expected from equivalent 
pathologic categories based on prior WECC pathologic data. Thus, clinical and pathologic 
categories do not share prognostic implications. This makes clinically based treatment decisions 
difficult and pre-treatment prognostication inaccurate. These data will be the basis for the 8th 
edition cancer staging manuals following risk adjustment for patient characteristics, cancer 
categories, and treatment characteristics and should direct 9th edition data collection.
Keywords
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INTRODUCTION
Initial therapeutic decisions for patients with esophageal cancer, the goal of which is to 
maximize survival while minimizing cancer treatment harm, are driven largely by clinical 
cancer staging information. Assignment of clinical stage grouping (cTNM) has, by tradition, 
shared pathologic stage groupings (pTNM) corresponding to cTNM, but whether prognostic 
significance of pTNM is shared with cTNM is uncertain.
To address this uncertainty, a six-continent Worldwide Esophageal Cancer Collaboration 
(WECC) was mounted to collect patient characteristics, clinical esophageal cancer 
categories, and all-cause mortality to (i) test the hypothesis that clinical and pathologic 
categories share the same prognostic implications; (ii) facilitate pre-treatment 
prognostication; (iii) improve clinical decision-making; and (iv) prepare for the 8th edition 
of the cancer staging manuals following risk adjustment. In this paper, we simply report the 
descriptive dataset of patient characteristics and cancer categories of individuals with 
clinically staged cancers and non–risk-adjusted survival that begin to address these aims.
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PATIENTS AND METHODS
Data
In 2012, 79 institutions were invited to participate in WECC, aimed at constructing refined 
data-driven esophageal cancer staging for the 8th edition of the cancer staging manuals. 
They were invited based on known volumes, indication that they had accessible data, and 
location around the world. Of these, 41 institutions obtained local ethics-board approval of 
databases and executed data-use agreements with Cleveland Clinic. Data were requested in 
completely de-identified form (Health Insurance Portability and Accountability Act research 
standards) for analysis, using a set of required variables with standard definitions. Variables 
included demographics, comorbidities, cancer categories, cancer treatment, and time-related 
outcomes. The Case Cancer Institutional Review Board of Case Western Reserve University 
and the Cleveland Clinic Institutional Review Board approved the entire project. This paper 
reports results of clinical data from 33 institutions whose data were submitted by September 
30, 2014, and were cleaned and adjudicated (Table A1 in Appendix).
Patients
At these institutions, of 22,654 patients (supporting information Table S1) with epithelial 
cancers, the majority were older men with normal body mass index, no weight loss, and 0–1 
Eastern Cooperative Oncology Group (ECOG) performance status. Comorbidities were 
present in a minority of patients, with cardiopulmonary comorbidities predominating. 
Among the 22,654 patients, 22,123 had clinical staging data available before treatment. 
These data revealed that patients with pure adenocarcinoma were older than those with pure 
squamous cell carcinoma (Table 1), were far less likely to be female, were considerably 
larger, and were more likely to have diabetes, coronary artery disease, and hypertension; 
however, they were in better ECOG status and had normal FVC. Although six continents are 
represented, most patients in the dataset were treated in North America, Europe, and Asia. 
Patients with adenocarcinoma lived predominantly in the West and those with squamous cell 
carcinoma in the East.
Endpoint
The endpoint was all-cause mortality from the first management decision. Median potential 
follow-up,1 if there were no deaths, was 8.9 years (25% >13.4 years, 10% >20 years), but 
considering deaths in this elderly population with a rapidly lethal cancer, overall median 
follow-up was 1.6 years; median follow-up for surviving patients was 2.5 years, with 25% 
followed more than 5.1 years and 10% more than 8.4 years.
Data analysis
For analysis, patients with adenosquamous and undifferentiated carcinoma (supporting 
information Table S2) were considered in both the squamous cell carcinoma and 
adenocarcinoma datasets. Survival was estimated using the Kaplan–Meier method, and these 
estimates are accompanied by 68% confidence limits, equivalent to ±1 standard error. 
Survival has been simply stratified by a number of patient characteristics and cancer 
categories, with no risk adjustment. The hazard function for death was estimated by a 
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parametric temporal decomposition method (for additional details, see http://
www.lerner.ccf.org/qhs/software/hazard).2 Continuous variables are summarized by mean ± 
standard deviation and categorical variables by frequency and percentage.
RESULTS
Clinical cancer categories
Histopathologic cell type was squamous cell carcinoma in 8,156, adenocarcinoma in 13,814, 
adenosquamous carcinoma in 116, and undifferentiated carcinoma in 37. Approximately a 
third of all cancers were confined to the esophageal wall (cT2 or less) for both squamous 
cell carcinoma and adenocarcinoma (Table 2 and supporting information Tables S3 and S4). 
Fewer than half the patients were free of regional lymph node metastasis (cN0), and few 
cancers had distant metastases (cM). The majority of cancers were G2/G3. 
Adenocarcinomas were located predominantly in the lower esophagus, and squamous cell 
carcinomas in the middle and lower esophagus. Otherwise, cancer categories differed only 
modestly.
Non–risk-adjusted survival
Overall survival was 98, 74, 36, and 24% at 30 days and 1, 5, and 10 years, respectively 
(supporting information Fig. S1). For both histopathologic cell types, risk of death peaked at 
1 year, then gradually decreased and plateaued by about 5 years to a near constant rate of 8% 
per year (supporting information Fig. S2).
Clinical categories (cTNM)—Survival was similar for patients with cTis and cT1 
cancers, but better for those with adenocarcinoma than squamous cell cancer (Fig. 1). It 
decreased with increasing cT for cT2-4a cancers. Survival decreased with increasing cN for 
adenocarcinoma but not for squamous cell carcinoma (Fig. 2). These decreases were much 
more distinctive with increasing cT for squamous cell carcinoma than for adenocarcinoma 
when stratified by cN0 (because of the better survival of patients with cTis-cT1 
adenocarcinomas) (Fig. 3) and cN+ (Fig. 4). Survival was poor in the presence of distant 
metastases (cM1) (Fig. 5). Generally, patients with early cancers had worse survival, and 
those with advanced cancers better survival, than expected from equivalent pathologic 
categories based on prior WECC data.
Other cancer categories—Survival decreased with increasing histologic grade for G1-4 
cancers (supporting information Fig. S3); however, it was considerably better for patients 
with G1 adenocarcinomas than those with squamous cell carcinoma. Survival increased with 
a more distal location of cancer within the esophagus (supporting information Fig. S4).
Other characteristics—Survival decreased with advancing age (supporting information 
Fig. S5) and was worse for men with squamous cell carcinoma than for women, but similar 
between sexes for adenocarcinoma (supporting information Fig. S6). Survival was highly 
heterogeneous among institutions (supporting information Fig. S7).
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DISCUSSION
Appropriateness of shared stage categories
Comparing survival based on clinical cancer categories to that of equivalent pathologic 
categories based on esophagectomy alone for the 7th edition of the cancer staging 
manuals,3,4 it is evident that prognostic implications for clinical categories will not be 
equivalent to those of pathologic categories, contrary to our initial hypothesis. The prognosis 
for these clinically staged early cancers was clearly worse, indicating that cTNM for these 
cancers was understaged compared to pTNM. This is particularly troublesome for 
therapeutic decisions about endoscopic therapies performed under the assumption that the 
cancer is early stage, without regional nodal or distant metastases. Prognostication for these 
early clinically staged cancers will be overly optimistic. Conversely, apparently advanced 
cTNM cancers carry a somewhat better prognosis than equivalent pTNM cancers. In part, 
this may be due to clinically overstaging early cancers and in part to the effect of 
neoadjuvant and adjuvant therapy for more advanced stage cancers. This is troublesome 
because it may expose patients with clinically overstaged early cancers and non-responders 
to unnecessary or ineffective neoadjuvant therapy.
Principal findings
Clinical staging appeared to be adequate for separating early cTis-1NOMO cancers from 
more advanced cancers, with survival better and more distinctive for adenocarcinoma than 
squamous cell carcinoma, but discrimination among early cancers was poor. Discrimination 
among advanced cancers was slightly better, but of questionable practical value. These 
observations highlight the deficiencies of current clinical staging.
WECC and data assemblage
WECC data for the 7th edition staging manuals was based on pathologic staging of patients 
undergoing esophagectomy alone.3–6 This new WECC effort included collecting clinical 
staging data for patients undergoing all treatments. The number of patient characteristic 
variables was greater and the data more complete than in the prior WECC effort. Thus, this 
was a global effort of considerable magnitude across geography, institutions, patients, cancer 
categories, and treatments. These data will be the basis for the 8th edition cancer staging 
manuals following risk adjustment for all these variables.
Clinical patient characteristics
In this WECC experience, esophageal cancer was found to be a disease of older men, 
although more so for adenocarcinoma than squamous cell carcinoma. Because the majority 
of patients underwent treatment with curative intent, most had good to excellent 
performance status, and no weight loss. Comorbidities were numerous and clinically 
significant; collection of these data was essential for risk adjustment of all-cause mortality.
Clinical cancer categories
The majority of cancers were locally advanced, with invasion into the adventitia (cT3) and 
metastases to regional lymph nodes (cN+). However, except for cancers so advanced that 
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only palliative therapy was offered, there were a sufficient number of patients to provide a 
wide spectrum of clinically staged esophageal cancers.
Histologic grade 2 and 3 predominated in both cell types. There was a smaller proportion of 
grade 1 cancers in this dataset than in the prior WECC effort,1 because it includes more than 
esophagectomy-only patients. G4 cancers were uncommon. Location was predominately 
lower thoracic esophagus; few patients had adenocarcinoma of the middle thoracic 
esophagus and rarely of the upper thoracic esophagus. Distribution of location for squamous 
cell carcinoma, although skewed to the middle and lower thoracic esophagus, will be 
sufficient to permit analysis of the effect of location on risk-adjusted survival. No patient 
with cervical esophageal cancer was included in the dataset.
Non–risk-adjusted survival
The endpoint for this study was all-cause mortality. This was chosen because it is a hard 
endpoint not requiring interpretation. Recording multiple patient comorbidities will permit 
extensive risk adjustment, which provides a truer reflection of death due to cancer than the 
softer endpoint of disease-specific mortality.7–9
Overall survival was similar for squamous cell carcinoma and adenocarcinoma. This 
surprising fact reflects important differences in patient characteristics and cancer categories 
between these groups. Except for cTisN0M0 and cT1N0M0 cancers, unadjusted survival 
was more distinctive when combining cT with cN. Survival was distinctive for histologic 
grades cG1–G4 and location. Regardless of histopathologic cell type, survival curves for 
cancer categories ‘pinched’ together compared with pathologic staging.3 This ‘regression 
toward the mean’ has many possible explanations, including (i) understaging of early 
clinical cancers accentuated by the ceiling of cTis; (ii) failure to use, or ineffectual use of, 
staging modalities such as endoscopic mucosal resection (EMR), EUS-FNA (endoscopic 
ultrasound-directed fine needle aspiration), and CT-PET for suspected early cancers; (iii) 
overstaging of advanced clinical cancers due to a floor of cT4b, cN3, and cM1; and (iv) 
unpredictability of effectiveness of neoadjuvant treatment (downstaging) of advanced 
clinical cancers, resulting in intermediate survival for some of these cancers that have poor 
pretreatment prognosis. This highlights the need for risk adjustment and a type of 
multivariable analysis that accounts for treatment effects as well as patient and cancer 
categories.
Strengths and limitations
Currently, this is the best attempt at providing worldwide clinical esophageal cancer staging 
data. However, clinical staging was not uniform among centers or across continents, and 
these heterogeneities generated heterogeneous survival. Patients treated in North America, 
Europe, and Asia predominated. Unlike most registry data, WECC collected more patient 
characteristics, cancer categories, and specific treatments. However, values for some 
variables were not recorded (missing data). Patients included in the study were undoubtedly 
biased away from metastatic cancer and palliative treatment. Data were similarly limited for 
untreatable patients, such as those with T4b and M1 cancers.
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The dataset also reflects temporal changes in treatment from esophagectomy alone to 
neoadjuvant therapy for advanced cancer. Nevertheless, older data on esophagectomy alone, 
which may seem a limitation, are crucial for developing pathologic staging of advanced 
esophageal cancers.
A limitation of this pure data presentation is that it does not account for patient variables that 
affect all-cause mortality; the interplay among TNM, histopathologic cell type, histologic 
grade, and cancer location in part due to the unique lymphatic anatomy of the esophagus; 
and the confounding of treatment effects, temporal factors, etiology, diagnosis, and clinical 
decision-making around the world.
Clinical staging implications
Today, esophagogastroduodenoscopy (EGD) and biopsy are necessary for determining 
location, histopathologic cell type, and histologic grade; EMR and EUS for cT; EUS-FNA 
for cN; and CT-PET for cM and cN; supplemented by ancillary imaging, aspiration, or 
biopsy.
Comprehensive clinical staging as described is problematic because of varying cost 
limitations and regional availability of staging modalities. Minimal worldwide standards for 
clinical staging must be set with worldwide adherence expected. Recording how clinical 
stage was obtained is necessary to determine quality of clinical staging. There is a need for 
more accurate and precise clinical staging modalities. Addition of other patient 
characteristics and cancer categories will permit better treatment decisions and more 
accurate pre-treatment prognostication.
CONCLUSIONS
Comparing these clinical data with WECC pathologic data for the 7th edition cancer staging 
manuals,3 it became evident that clinical categories did not share the same prognostic 
implications as pathologic categories after esophagectomy alone. The pinching of survival 
data makes pre-treatment prognostication difficult, providing overly optimistic 
prognostication for patients with early-stage cancers and overly pessimistic prognostication 
for those with advanced clinical stage cancers. This makes clinical decision-making difficult.
These clinical staging data will be the basis for the 8th edition cancer staging manuals 
following risk adjustment for many confounding variables. These findings should direct data 
collection for the 9th edition. This is a milestone in the clinical staging of esophageal cancer 
and provides direction for future advancements.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
Table A1
Worldwide Esophageal Cancer Collaboration: Participating institutions and investigators
Institution Location Investigators
Beijing Cancer Hospital, Peking University 
Cleveland Clinic
Beijing, China Cleveland, OH, 
USA
Ken N. Chen Thomas W. Rice 
Eugene H. Blackstone
Case Western Reserve University Erasmus 
Medical Center
Cleveland, OH, USA 
Rotterdam, The Netherlands
Carolyn Apperson-Hansen Bas P.L. 
Wijnhoven, Jan van Lanschot, 
Sjoerd Lagarde
Fourth Hospital of Hebei Medical University 
Fox Chase Cancer Center
Shijiazhuang, Hebei, China 
Philadelphia, PA, USA
Jun-Feng Liu Walter J. Scott Donna 
Edmondson
Groote Schuur Hospital, University of Cape 
Town Guy’s & St. Thomas’ Hospitals
Cape Town, South Africa 
London, UK
Riette Burger Andrew R. Davies, 
Janine Zylstra
Helsinki University Hospital Helsinki, Finland Jari V. Räsänen, Jarmo A. Salo, 
Yvonne Sundstrom
Hospital Universitario del Mar Barcelona, Spain Manuel Pera
Hôpital Nord Marseille, France Xavier B. D’Journo
Indiana University Medical Center Indianapolis, IN, USA Kenneth A. Kesler
University of Texas MDAnderson Hospital Houston, TX, USA Wayne L. Hofstetter Arlene Correa, 
Stephen G. Swisher
Mayo Clinic Rochester, MN, USA Mark S. Allen
Medical University of South Carolina Charleston, SC, USA Chad E. Denlinger
Memorial Sloan-Kettering Cancer Center New York, NY, USA Valerie W. Rusch
University of Queensland, Princess 
Alexandra Hospital
Brisbane, Australia B. Mark Smithers, David Gotley, 
Andrew Barbour, Iain Thomson
University of Newcastle upon Tyne Newcastle upon Tyne, UK S. Michael Griffin, Jon Shenfine
Oregon Health & Science University Portland, OR, USA Paul H. Schipper, John G. Hunter
Royal Marsden NHS Foundation Trust London, UK William H. Allum
Shanghai Chest Hospital Shanghai, China Wentao (Vincent) Fang
Toronto General Hospital Toronto, ON, Canada Gail E. Darling
University Zeikenhuizen Leuven Leuven, Belgium Tony E.M.R. Lerut, Phillipe R. 
Nafteux
University Medical Center Utrecht Utrecht, The Netherlands Richard van Hillegersberg
University of Alabama at Birmingham Birmingham, AL, USA Robert J. Cerfolio
Hospital de Clinicas, University of Buenos 
Aires
Buenos Aires, Argentina Luis Durand, Roberto De Antón
The University of Chicago, Department of 
Surgery
Chicago, IL, USA Mark K. Ferguson
University of Hong Kong Medical Center, 
Queen Mary Hospital
Hong Kong, China Simon Law
University of Michigan Ann Arbor, MI, USA Mark B. Orringer, Becky L. 
Marshall
University of Montreal Montreal, Quebec, Canada Andre Duranceau, Susan Howson
University of Pittsburgh Medical Center Pittsburgh, PA, USA James D. Luketich, Arjun 
Pennathur, Kathy Lovas
University of Rochester Rochester, NY, USA Thomas J. Watson
University of São Paulo São Paulo, Brazil Ivan Cecconello
West China Hospital of Sichuan University Chengdu, Sichuan, China Long-Qi Chen
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Fig. 1. 
Survival by clinical cT category. Kaplan–Meier estimates accompanied by vertical bars 
representing 68% confidence limits, equivalent to ±1 standard error. (A) Squamous cell 
carcinoma and (B) adenocarcinoma. [Color figure can be viewed in the online issue, which 
is available at wileyonlinelibrary.com.]
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Fig. 2. 
Survival by clinical cN category. Format is as in Fig. 1. (A) Squamous cell carcinoma and 
(B) adenocarcinoma. [Color figure can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
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Fig. 3. 
Survival by cT category for cN0 cancers. Format is as in Fig. 1. (A) Squamous cell 
carcinoma and (B) adenocarcinoma. [Color figure can be viewed in the online issue, which 
is available at wileyonlinelibrary.com.]
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Fig. 4. 
Survival by cT category for cN+ cancers. Format is as in Fig. 1. (A) Squamous cell 
carcinoma and (B) adenocarcinoma. [Color figure can be viewed in the online issue, which 
is available at wileyonlinelibrary.com.]
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Fig. 5. 
Survival by clinical cM category. Format is as in Fig. 1. (A) Squamous cell carcinoma and 
(B) adenocarcinoma. [Color figure can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
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Table 1
Patient characteristics of those with pure squamous cell carcinoma and pure adenocarcinoma of the esophagus
Characteristic†
Squamous cell carcinoma (total n = 8,156) Adenocarcinoma (total n = 13,814)
n* No. (%) or mean ± SD n* No. (%) or mean ± SD
Demographics
 Age (years) 8,077 61 ± 9.9 13,373 63 ± 10
 Female 8,156 2,455 (30) 13,812 1,882 (14)
 Body mass index (mg/kg2) 4,427 22 ± 3.7 7,226 27 ± 5.1
 Weight loss (kg) 4,590 1.9 ± 4.9 6,726 2.8 ± 9.2
Comorbidities
 ECOG performance status 3,104 3,178
  0 739 (24) 1,156 (36)
  1 549 (18) 1,755 (55)
  2 1,269 (41) 178 (5.6)
  3 540 (17) 80 (2.5)
  4 7 (0.23) 11 (0.35)
 Diabetes 7,436 322 (4.3) 11,606 1,430 (12)
  IDDM 7,365 58 (0.79) 11,127 185 (1.7)
  NIDDM 7,365 193 (2.6) 11,127 766 (6.9)
 Coronary artery disease 4,263 269 (6.3) 6,117 993 (16)
 Arrhythmia 3,862 79 (2) 4,127 119 (2.9)
 Hypertension 5,734 1,120 (20) 9,168 2,753 (30)
 Peripheral arterial disease 4,811 114 (2.4) 6,937 235 (3.4)
 Smoker 5,094 3,664 (72) 9,457 6,439 (68)
  Past 4,412 1,442 (33) 7,553 2,993 (40)
  Current 4,412 1,540 (35) 7,553 1,542 (20)
 FEV1 (% of predicted) 3,823 96 ± 21 5,605 95 ± 20
 FVC (% of predicted) 3,468 110 ± 21 3,922 100 ± 18
 Creatinine (μmol/L) 2,686 76 ± 17 1,448 75 ± 28
 Bilirubin (μmol/L) 2,583 12 ± 6.2 1,019 11 ± 6.8
Decade 8,129 13,798
 1970–1979 127 (1.6) 45 (0.33)
 1980–1989 1,291 (16) 427 (3.1)
 1990–1999 1,427 (18) 3,441 (25)
 2000–2009 3,185 (39) 7,614 (55)
 2010–2014 2,099 (26) 2,271 (16)
Continent 8,156 13,814
 North America 1,937 (24) 7,814 (57)
 Europe 1,473 (18) 4,143 (30)
 Asia 4,041 (50) 360 (2.6)
 Australia 597 (7.3) 1,280 (9.3)
 South America 80 (0.98) 209 (1.5)
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Characteristic†
Squamous cell carcinoma (total n = 8,156) Adenocarcinoma (total n = 13,814)
n* No. (%) or mean ± SD n* No. (%) or mean ± SD
 Africa 28 (0.34) 8 (0.058)
*
Patients with data available.
†
Patient characteristics of those with adenosquamous and undifferentiated carcinoma are shown in supporting information Table S2. ECOG, 
Eastern Cooperative Oncology Group; FEV1 (%), forced expiratory volume in 1 second (percent of predicted); FVC (%), forced vital capacity 
(percent of predicted); IDDM, insulin-dependent diabetes mellitus; NIDDM, non–insulin-dependent diabetes mellitus; SD, standard deviation.
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Table 2
Clinical cancer categories of patients with pure squamous cell carcinoma and pure adenocarcinoma of the 
esophagus
Category Squamous cell carcinoma (n = 8,156)
No. (%)
Adenocarcinoma (n = 13,814) No.
(%)
cT
 cT0 19 (0.3) 160 (1.5)
 cTis 67 (1.1) 214 (2)
 cT1 556 (8.9) 1,469 (14)
 cT2 1,327 (21) 2,346 (22)
 cT3 3,297 (53) 6,094 (57)
 cT4a 1,000 (16) 385 (3.6)
 cTX 1,890 3,146
cN
 cN0 2,522 (40) 5,009 (47)
 cN+ 3,785 (60) 5,725 (53)
  cN1 1,520 (79)† 256 (73)‡
  cN2 371 (19)† 82 (23)‡
  cN3 45 (2.3)† 15 (4.2)‡
 cNX 1,849 3,080
cM
 cM0 7,850 (96) 12,981 (94)
 cM1 306 (3.8) 833 (6.0)
Grade§
 cG1 307 (9.2) 370 (11)
 cG2 1,494 (45) 1,367 (42)
 cG3 1,519 (46) 1,553 (47)
 cG4¶ 0 (0) 0 (0)
 cGX 4,836 10,524
Location
 cUpper 990 (13) 97 (0.83)
 cMiddle 3,573 (48) 456 (3.9)
 cLower 2,938 (39) 11,137 (95)
 cLocationX 655 2,124
Clinical cancer categories of patients with adenosquamous and undifferentiated carcinoma are shown in supporting information Table S4.
†
Data available for 1,936 patients.
‡
Data available for 353 patients.
§G1, well differentiated; G2, moderately well differentiated; G3, poorly differentiated; G4, undifferentiated.
¶G4 cancers are reported in supporting information Table S4.
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